Use of a "CNI holidays" strategy in acute renal dysfunction late after heart transplant. Report of two cases.

Autores de IIS La Fe

• Pau Alonso Fernández

  Autor

• Ignacio José Sánchez Lázaro

  Autor

• Luis Almenar Bonet

  Autor

• 

  Luis Vicente Martínez Dolz

  Autor

• Ana Andrés Lahuerta

  Autor

• Antonio Salvador Sanz

  Autor

• José Anastasio Montero Argudo

  Autor

Grupos

• Grupo de Investigación Clínica y Traslacional en Cardiología

• Regeneración y Trasplante Cardíaco

Abstract

BACKGROUND: Acute renal dysfunction (ARD) may appear in heart transplant (HTx) patients both in the early postoperative period and during follow-up, even after several years. CD25 is a subunit of the interleukin-2 receptor which is found exclusively on activated CD4 T lymphocytes. CD25 is crucial for clonal expansion of anti-allograft host lymphocytes that mediate in acute rejection. There are experiences supporting the use of Anti-CD25 monoclonal antibodies (MAb) immediately after HTx in patients with ARD as a bridge to renal function recovery, allowing the temporary suspension of treatment with CNI. METHODS: In this study we report two cases of successful use of weekly MAb (basiliximab) in HTx patients who developed late ARD after HTx. CONCLUSIONS: In coclusion, we think that in cases of ARD where CNI therapy plays a key role, the use of weekly doses of basiliximab allows CNI discontinuation until the restoration of renal function is achieved.

Keywords

• Basiliximab; CNI holiday; Heart transplant